Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05197270 · ClinicalTrials.gov registry record · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1 study of Neovascular (Wet) Age-Related Macular Degeneration, sponsored by 4D Molecular Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 215
- Enrollment target
- 20
- Study locations
NCT05197270 is a Phase 1 study of Neovascular (Wet) Age-Related Macular Degeneration that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 215 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05197270, a Phase 1 study of Neovascular (Wet) Age-Related Macular Degeneration, is actively recruiting participants, sponsored by 4D Molecular Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 215 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Conditions Studied
Interventions
- BIOLOGICAL 4D-150 IVT
- BIOLOGICAL Aflibercept IVT
Study Locations (20)
Florida
- Rand Eye Institute - Deerfield Beach
- Retina Vitreous Consultants, LLP DBA Retina Group of Florida - Fort Lauderdale
- Vitreo Retinal Associates - Gainesville
- Florida Eye Associates - Melbourne
- Retinal Specialty Institute - Pensacola
- Retina Vitreous Associates of Florida - Tampa
California
- California Retina Consultants - Oxnard
- Retinal Consultants Medical Group - Sacramento
Arizona
- Barnet Delaney Perkins Eye Center - Phoenix
Colorado
- Colorado Retina Associates - Lakewood
Illinois
- University Retina and Macula Associates - Oak Forest
Indiana
- Retina Partners Midwest - Carmel
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Massachusetts
- Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2031-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05197270
The ClinicalTrials.gov registry entry for NCT05197270 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 4D Molecular Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular (Wet) Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT is the first listed.
NCT05197270 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05197270 about?
NCT05197270 is a clinical study titled "4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration". Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
What is the current status of trial NCT05197270?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2021-12-09. Estimated completion is 2031-01.
What conditions does trial NCT05197270 study?
This clinical trial studies the following conditions: Neovascular (Wet) Age-Related Macular Degeneration.
What interventions are being tested in trial NCT05197270?
The interventions under investigation include: 4D-150 IVT (BIOLOGICAL), Aflibercept IVT (BIOLOGICAL).
Who is sponsoring clinical trial NCT05197270?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05197270 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular (Wet) Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.